# 21 U.S.C. 379aa Serious adverse event reporting for nonprescription drugs

21 U.S.C. 379aa Serious adverse event reporting for nonprescription drugs, “Serious adverse event reporting for nonprescription drugs”, is a U.S. Code section of [Part H—Serious Adverse Event Reports](https://ontology.bommaritollc.com/id/01a0f06c-cbb0-75d7-baad-5a32119aae80); in force.

IRI: <https://ontology.bommaritollc.com/id/01a0f06c-cdef-72da-b70b-9f4e966513a5>

Within: [Title 21—Food and Drugs](https://ontology.bommaritollc.com/id/01a0f06c-cb65-7672-8fda-c39517ff08c0) › [Chapter 9—Federal Food, Drug, and Cosmetic Act](https://ontology.bommaritollc.com/id/01a0f06c-cb91-72e0-858b-060e8c845f23) › [Subchapter VII—General Authority](https://ontology.bommaritollc.com/id/01a0f06c-cba0-7476-aff5-2e37cf9afce5) › [Part H—Serious Adverse Event Reports](https://ontology.bommaritollc.com/id/01a0f06c-cbb0-75d7-baad-5a32119aae80)

Type: [schema:Legislation](https://schema.org/Legislation)

- `adms:identifier`: [usc-section 21 U.S.C. 379aa](https://ontology.bommaritollc.com/id/01a0f06c-cdf0-7257-80e5-71f131b08768)
- `eli:cites`:
  - [5 U.S.C. 552a Records maintained on individuals](https://ontology.bommaritollc.com/id/01a0edf4-5b2a-7323-97f5-3c302a86b070)
  - [21 U.S.C. 352 Misbranded drugs and devices](https://ontology.bommaritollc.com/id/01a0f06c-ccca-77a6-a36b-8f6a7374070e)
  - [21 U.S.C. 353 Exemptions and consideration for certain drugs, devices, and biological products](https://ontology.bommaritollc.com/id/01a0f06c-cccb-7545-90e2-a1651be32192)
  - [21 U.S.C. 355 New drugs](https://ontology.bommaritollc.com/id/01a0f06c-ccd6-7038-b7ea-5f9e1b3b3f50)
  - [21 U.S.C. 374 Inspection](https://ontology.bommaritollc.com/id/01a0f06c-cd83-7175-9624-79d9d7728390)
  - [21 U.S.C. 379v Safety report disclaimers](https://ontology.bommaritollc.com/id/01a0f06c-cdef-72da-b70b-9f3eed6ea101)
- `prov:wasDerivedFrom`:
  - [evidence from https://www.govinfo.gov/app/details/USCODE-2024-title21/USCODE-2024-title21-chap9-subchapVII-partH-sec379aa](https://ontology.bommaritollc.com/id/01a0f06c-cdef-72da-b70b-9f4df64fb401)
  - [evidence from https://www.govinfo.gov/app/details/](https://ontology.bommaritollc.com/id/01a0f06c-d183-71d6-a1d2-42f543f3eb2b)
  - [evidence from https://www.govinfo.gov/app/details/](https://ontology.bommaritollc.com/id/01a0f0d2-2dd9-721f-bf70-02b515837037)
  - [evidence from https://www.govinfo.gov/link/uscode/21/379aa?type=usc&year=mostrecent&link-type=details](https://ontology.bommaritollc.com/id/01a10f15-fe5d-70f5-977f-16747e01f037)
- `schema:isPartOf`: [Part H—Serious Adverse Event Reports](https://ontology.bommaritollc.com/id/01a0f06c-cbb0-75d7-baad-5a32119aae80)
- `schema:legislationIdentifier`: 21 U.S.C. 379aa
- `schema:legislationJurisdiction`: [United States](https://ontology.bommaritollc.com/id/01a0ed8e-f797-7004-b7f5-bec2695977c0)
- `schema:legislationLegalForce`: [schema:InForce](https://schema.org/InForce)
- `schema:legislationType`: [U.S. Code section](https://ontology.bommaritollc.com/vocab/leg/uscSection)
- `schema:name`: Serious adverse event reporting for nonprescription drugs
- `schema:url`: [https://www.govinfo.gov/link/uscode/21/379aa?type=usc&year=mostrecent&link-type=details](https://www.govinfo.gov/link/uscode/21/379aa?type=usc&year=mostrecent&link-type=details)
- `skos:prefLabel`: 21 U.S.C. 379aa Serious adverse event reporting for nonprescription drugs

## Elsewhere

- [Official page](https://www.govinfo.gov/link/uscode/21/379aa?type=usc&year=mostrecent&link-type=details) (www.govinfo.gov)
- [Source](https://www.govinfo.gov/app/details/USCODE-2024-title21/USCODE-2024-title21-chap9-subchapVII-partH-sec379aa) (www.govinfo.gov)
- [Source](https://www.govinfo.gov/app/details/) (www.govinfo.gov)

## Pointing here

- Cited by (4; `eli:cites`):
  - [21 U.S.C. 331 Prohibited acts](https://ontology.bommaritollc.com/id/01a0f06c-cc92-7163-972f-ca345be44724)
  - [21 U.S.C. 352 Misbranded drugs and devices](https://ontology.bommaritollc.com/id/01a0f06c-ccca-77a6-a36b-8f6a7374070e)
  - [21 U.S.C. 353 Exemptions and consideration for certain drugs, devices, and biological products](https://ontology.bommaritollc.com/id/01a0f06c-cccb-7545-90e2-a1651be32192)
  - [21 U.S.C. 381 Imports and exports](https://ontology.bommaritollc.com/id/01a0f06c-cdf5-70c8-b8d2-b17f8ad341e4)
- Its changes, from (1; `eli:changes`):
  - [Pub. L. 109-462](https://ontology.bommaritollc.com/id/01a0f06c-d2da-73c3-821d-02c1dbea6946)
- Rules made under it (1; `eli:based_on`):
  - [21 CFR Part 329—Nonprescription human drug products subject to section 760 of the Federal food, drug, and cosmetic act](https://ontology.bommaritollc.com/id/01a0f094-b853-7301-b224-60005b18c5ed)

---
Also as: [Turtle](https://ontology.bommaritollc.com/id/01a0f06c-cdef-72da-b70b-9f4e966513a5.ttl), [JSON-LD](https://ontology.bommaritollc.com/id/01a0f06c-cdef-72da-b70b-9f4e966513a5.jsonld), [N-Triples](https://ontology.bommaritollc.com/id/01a0f06c-cdef-72da-b70b-9f4e966513a5.nt), [HTML](https://ontology.bommaritollc.com/id/01a0f06c-cdef-72da-b70b-9f4e966513a5)
Cite as: 21 U.S.C. 379aa Serious adverse event reporting for nonprescription drugs. bc-ontology, release 0.1.0-rc38, 2026-10-21. https://ontology.bommaritollc.com/id/01a0f06c-cdef-72da-b70b-9f4e966513a5
Release 0.1.0-rc38, graph hash 05350a11cf9d0c42fba51e92b877115781ab65cb92afcd6b172ff9f8f4abf0bd.
